Pacira announced new data showing that a patient-optimizing, opioid-sparing enhanced recovery after surgery, or ERAS, pathway, which includes intraoperative infiltration with Exparel, results in high rates of early discharge and patient satisfaction among Medicare-insured patients undergoing total knee or hip arthroplasty, or TKA and THA. Findings also demonstrate that the vast majority of patients do not require more than a 7-day opioid prescription following discharge. The research was detailed during a podium presentation at the American Academy of Orthopaedic Surgeons, or AAOS. Retrospective chart review data were captured for 645 consecutive Medicare patients who underwent primary inpatient TKA or THA between June 1, 2015, and November 16, 2017. All patients followed a procedure-specific ERAS protocol. Overall, 84% of patients were same-day discharged to home, without home services, following their joint replacement and 84.2% did not require any additional opioid prescriptions beyond the initial 7-day prescription provided at discharge. Nationally, 38% of knee replacement patients are still taking opioids two months after surgery.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.